Haemoptysis management in cystic fibrosis: A case report and treatment pathway

J Clin Pharm Ther. 2020 Aug;45(4):845-847. doi: 10.1111/jcpt.13179. Epub 2020 Jun 1.

Abstract

What is known and objective: Haemoptysis is a major complication of cystic fibrosis (CF) and is associated with pulmonary exacerbations and admission to the hospital. The US CF Pulmonary Foundation guidelines fail to reach consensus on haemoptysis treatment regarding pharmacotherapy options.

Case summary description: We describe a case in which systemic tranexamic acid was utilized to treat haemoptysis in a CF adult patient who was experiencing progressively worsening haemoptysis despite numerous bronchial artery embolization procedures.

What is new and conclusion: The use of antifibrinolytic agents may be of potential benefit in refractory haemoptysis episodes in adult CF patients.

Keywords: cystic fibrosis; haemoptysis; hospitalization; tranexamic acid.

Publication types

  • Case Reports

MeSH terms

  • Antifibrinolytic Agents / therapeutic use*
  • Cystic Fibrosis / complications*
  • Embolization, Therapeutic
  • Hemoptysis / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Tranexamic Acid / therapeutic use*

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid